Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Nilvadipine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 75530-68-6, Escor, Nivadil, Nivadipine, Fr-34235, Fk 235
    Molecular Formula
    C19H19N3O6
    Molecular Weight
    385.4  g/mol
    InChI Key
    FAIIFDPAEUKBEP-UHFFFAOYSA-N
    FDA UNII
    0214FUT37J
    Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-O-methyl 5-O-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
    2.1.2 InChI
    InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
    2.1.3 InChI Key
    FAIIFDPAEUKBEP-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C
    2.2 Other Identifiers
    2.2.1 UNII
    0214FUT37J
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 5-isopropyl-3-methyl-2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinecarboxylate

    2. Escor

    3. Fr 34235

    4. Fr-34235

    5. Nivadil

    2.3.2 Depositor-Supplied Synonyms

    1. 75530-68-6

    2. Escor

    3. Nivadil

    4. Nivadipine

    5. Fr-34235

    6. Fk 235

    7. Nivadip

    8. Dl-nilvadipine

    9. Fr 34235

    10. Sk&f 102,362

    11. Cl 287,389

    12. Fk-235

    13. Cl-287389

    14. Nilvadipine (arc029)

    15. Sk&f-102362

    16. 5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    17. 3-o-methyl 5-o-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    18. Cl-287,389

    19. 0214fut37j

    20. 5-isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

    21. Skf-102362

    22. 3,5-pyridinedicarboxylic Acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) Ester

    23. Fr34235

    24. Ncgc00167435-01

    25. Sk&f-102,362

    26. Nilvadipinum [latin]

    27. Nilvadipino [spanish]

    28. Nivaldipine

    29. Nilvadipino

    30. Nilvadipinum

    31. 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-methyl 5-(1-methylethyl) Ester

    32. Nilvadipine [usan:inn:jan]

    33. Arc029

    34. Brn 3572609

    35. Unii-0214fut37j

    36. Nivadil (tn)

    37. Mfcd00867065

    38. Nilvadipine [mi]

    39. Nilvadipine [inn]

    40. Nilvadipine [jan]

    41. Nilvadipine [usan]

    42. Dsstox_cid_26624

    43. Dsstox_rid_81774

    44. Nilvadipine [mart.]

    45. Dsstox_gsid_46624

    46. Schembl33729

    47. (+/-)-nilvadipine

    48. Nilvadipine [who-dd]

    49. Chembl517427

    50. Dtxsid2046624

    51. Chebi:31911

    52. Faiifdpaeukbep-uhfffaoysa-

    53. Gtpl10160

    54. Nilvadipine (jp17/usan/inn)

    55. Fk235

    56. Hms3651j11

    57. Hms3714a17

    58. Hms3884f16

    59. Bcp06007

    60. Arc029;fr34235

    61. Tox21_112439

    62. Bdbm50103634

    63. Akos015907577

    64. Ccg-220648

    65. Db06712

    66. Ks-1303

    67. Ncgc00167435-02

    68. Ncgc00167435-03

    69. Ncgc00167435-07

    70. 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 5-isopropyl 3-methyl Ester

    71. 3,5-pyridinedicarboxylic Acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl-5-(1-methylethyl) Ester

    72. 3-methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    73. 5-isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate

    74. Ac-28326

    75. Hy-14284

    76. O3-methyl O5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    77. Cas-75530-68-6

    78. Db-055963

    79. Ft-0630839

    80. N0899

    81. S2721

    82. Sw219572-1

    83. D01908

    84. Ab01566895_01

    85. 530n686

    86. A838445

    87. Sr-01000872715

    88. Q7037489

    89. Sr-01000872715-1

    90. O3-methyl O5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-

    91. (+)-5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    92. 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic Acid O3-methyl Ester O5-propan-2-yl Ester

    93. 5-isopropyl 3-methyl (+)-2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    94. 5-isopropyl 3-methyl (-)-2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    95. 5-isopropyl3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 385.4 g/mol
    Molecular Formula C19H19N3O6
    XLogP32.9
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count6
    Exact Mass385.12738533 g/mol
    Monoisotopic Mass385.12738533 g/mol
    Topological Polar Surface Area134 Ų
    Heavy Atom Count28
    Formal Charge0
    Complexity783
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    For the management of vasospastic angina, chronic stable angina and hypertension.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Nilvadipine is similar to other dihydropyridines including amlodipine, felodipine, isradipine, and nicardipine. Nilvadipine is used to treat Prinzmetal's angina, hypertension, and other vascular disorders such as Raynaud's phenomenon. By blocking the calcium channels, Nifedipine inhibits the spasm of the coronary artery and dilates the systemic arteries, results in a increase of myocardial oxygen supply and a decrease in systemic blood pressure.

    5.2 MeSH Pharmacological Classification

    Calcium Channel Blockers

    A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)

    Antihypertensive Agents

    Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)

    5.3 ATC Code

    C - Cardiovascular system

    C08 - Calcium channel blockers

    C08C - Selective calcium channel blockers with mainly vascular effects

    C08CA - Dihydropyridine derivatives

    C08CA10 - Nilvadipine

    5.4 Mechanism of Action

    Nilvadipine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.